Nikolaos Lazaridis

Nov 1, 2024 | sciencedirect.com | Nikolaos Lazaridis |Edward J Despott |Debra J. Palmer |Y. Ho Shin

Section snippetsReal-world data studiesIn children 6 to 11 years of age, the efficacy and safety of omalizumab as add-on therapy supported by randomized controlled trial (RCT) evidence have been confirmed in real-world studies (RWS) (Table I).

Jan 13, 2024 | mdpi.com | Edward J Despott |Nikolaos Lazaridis |Alessandro Rimondi |Rocio Chacchi-Cahuin

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.